Table 1. Description of the studies included in the pooled analysis of the ESR2 rs1271572 and ovarian carcinoma risk.

Study Name	Location	Study Design	White non-Hispanic women
			Cases (invasive)		Controls
			N	Mean age (SE), yrs	N	Mean age (SE), yrs
AUS (Australian National Ovarian Cancer Study)	Australia	Population-based case-control	1051	58.5 (0.3)	1148	56.7 (0.3)
BAV (Bavarian Ovarian Cancer Cases and Controls)	Bavaria, Germany	Hospital based	204	56.0 (0.7)	229	58.0 (0.7)
HAW (Hawaiian Ovarian Cancer Study)	Hawaii, USA	Population-based case-control	64	55.0 (1.3)	152	56.8 (0.9)
MAL (The Danish Malignant Ovarian Tumor Study)	Denmark		348	59.9 (0.6)	893	56.8 (0.4)
NCO (North Carolina Ovarian Cancer Study)	North Carolina, USA	Population-based case-control	520	57.8 (0.5)	582	55.2 (0.4)
POC (Polish Ovarian Cancer Study)	Szczecin, Poznan, Opole and Rzeszow, Poland	Population-based case-control	545	55.0 (0.5)	525	57.5 (0.5)
SEA (UK SEARCH Ovarian Cancer Study)	United Kingdom		936	56.0 (0.3)	1198	55.0 (0.3)
STA (Genetic Epidemiology of Ovarian Cancer)	California, USA	Population-based case-control	265	51.4 (0.7)	338	48.2 (0.6)
UKO (UK Ovarian Cancer Population Study)	United Kingdom		634	61.0 (0.4)	998	64.9 (0.3)
USC (Los Angeles County Case-Control Studies of Ovarian Cancer)	California, USA	Population-based case-control	379	58.0 (0.5)	519	56.3 (0.5)
POOLED			4946	57.3 (0.2)	6582	57.2 (0.1)